shot-button
Subscription Subscription
Home > News > India News > Article > COVID 19 Sharad Pawar visits vaccine maker Serum Institute of India

COVID-19: Sharad Pawar visits vaccine-maker Serum Institute of India

Updated on: 02 August,2020 09:30 PM IST  |  Mumbai
PTI |

sII has signed an agreement to manufacture a potential coronavirus vaccine being developed by Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca

COVID-19: Sharad Pawar visits vaccine-maker Serum Institute of India

Sharad Pawar at Serum Institute of India. Pic/Twitter Sharad Pawar

Nationalist Congress Party (NCP) chief Sharad Pawar visited Serum Institute of India (SII) here on Saturday afternoon.





SII has signed an agreement to manufacture a potential coronavirus vaccine being developed by Jenner Institute of Oxford University in collaboration with British-Swedish pharma company AstraZeneca.

Pawar later tweeted about his visit to the company.

Keep scrolling to read more news

Catch up on all the latest Crime, National, International and Hatke news here. Also download the new mid-day Android and iOS apps to get latest updates.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK